Lattice Biologics Ltd.
LBLTF
$0.00
$0.000.00%
OTC PK
| 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | 06/30/2020 | |
|---|---|---|---|---|---|
| Revenue | -28.88% | -3.39% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -28.88% | -3.39% | -- | -- | -- |
| Cost of Revenue | -36.74% | -8.53% | -- | -- | -- |
| Gross Profit | -13.73% | 5.90% | -- | -- | -- |
| SG&A Expenses | -38.99% | -15.09% | -- | -- | -- |
| Depreciation & Amortization | 36.28% | 56.61% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.58% | -5.85% | -- | -- | -- |
| Operating Income | 38.88% | 12.45% | -- | -- | -- |
| Income Before Tax | 51.67% | 35.33% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 51.67% | 35.33% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.67% | 35.33% | -- | -- | -- |
| EBIT | 38.88% | 12.45% | -- | -- | -- |
| EBITDA | 66.46% | 23.15% | -- | -- | -- |
| EPS Basic | 64.18% | 49.00% | -- | -- | -- |
| Normalized Basic EPS | 61.42% | 46.03% | -- | -- | -- |
| EPS Diluted | 64.18% | 49.00% | -- | -- | -- |
| Normalized Diluted EPS | 61.42% | 46.03% | -- | -- | -- |
| Average Basic Shares Outstanding | 33.85% | 28.36% | -- | -- | -- |
| Average Diluted Shares Outstanding | 33.85% | 28.36% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |